人乳头瘤病毒31型主要衣壳蛋白上型特异性和交叉反应性中和构象表位的鉴定
Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31.
作者信息
Fleury M J J, Touzé A, Alvarez E, Carpentier G, Clavel C, Vautherot J-F, Coursaget P
机构信息
INSERM U618, Université François Rabelais, Tours, France.
出版信息
Arch Virol. 2006 Aug;151(8):1511-23. doi: 10.1007/s00705-006-0734-y. Epub 2006 Mar 3.
Abstract
The majority of the neutralizing epitopes of papillomaviruses (PV) are conformation-specific and have not been fully characterised. Studies have, to date, been limited to a few HPV types only. We analysed the epitopes on the major capsid protein (L1) of Human papillomavirus (HPV) type 31 using monoclonal antibodies (MAbs) generated against HPV-31 virus-like particles (VLPs). The type-specific MAbs against HPV-31 were all found to be neutralizing and recognized conformation-dependent epitopes. Two other MAbs directed against a conformational epitope were found to be cross-reactive with other HPV types, and one of them was found to be cross-neutralizing. Cross-reactive antibodies were further investigated using wild-type HPV-16 L1 VLPs and two mutants. The results obtained suggested the existence of a cross-neutralizing conformational epitope at the N-terminal part of the FG loop of the major capsid protein, and the other four cross-reactive MAbs recognized epitopes also located at the N-terminal part of the FG loop.
摘要
乳头瘤病毒（PV）的大多数中和表位具有构象特异性，尚未得到充分表征。迄今为止，研究仅局限于少数几种人乳头瘤病毒（HPV）类型。我们使用针对人乳头瘤病毒31型（HPV-31）病毒样颗粒（VLP）产生的单克隆抗体（MAb），分析了HPV-31主要衣壳蛋白（L1）上的表位。所有针对HPV-31的型特异性MAb均具有中和作用，并识别构象依赖性表位。另外两种针对构象表位的MAb被发现与其他HPV类型具有交叉反应性，其中一种具有交叉中和作用。使用野生型HPV-16 L1 VLP和两种突变体对交叉反应性抗体进行了进一步研究。所得结果表明，在主要衣壳蛋白FG环的N端部分存在一个交叉中和性构象表位，其他四种交叉反应性MAb识别的表位也位于FG环的N端部分。
相似文献
1
Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31.人乳头瘤病毒31型主要衣壳蛋白上型特异性和交叉反应性中和构象表位的鉴定
Arch Virol. 2006 Aug;151(8):1511-23. doi: 10.1007/s00705-006-0734-y. Epub 2006 Mar 3.
2
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.人乳头瘤病毒L1主要衣壳蛋白内两个交叉中和线性表位的鉴定
J Virol. 2002 Jul;76(13):6480-6. doi: 10.1128/jvi.76.13.6480-6486.2002.
3
Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.人乳头瘤病毒16型主要衣壳蛋白FG表面环上的突变会影响型特异性中和抗体和交叉反应抗体的识别。
J Med Virol. 2005 Dec;77(4):558-65. doi: 10.1002/jmv.20492.
4
Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.杂交乳头瘤病毒L1分子组装成病毒样颗粒，这些颗粒可重构构象表位并诱导针对不同HPV类型的中和抗体。
Virology. 2001 Dec 20;291(2):324-34. doi: 10.1006/viro.2001.1220.
5
Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.针对人乳头瘤病毒6型L1病毒样颗粒的单克隆抗体，除了能识别6型特异性表位外，还能识别11型人乳头瘤病毒上的构象性和线性中和表位。
Virology. 1996 Oct 15;224(2):477-86. doi: 10.1006/viro.1996.0554.
6
Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles.人乳头瘤病毒31型L1/L2病毒样颗粒诱导的型特异性和交叉反应性抗体。
J Med Microbiol. 2007 Jul;56(Pt 7):907-913. doi: 10.1099/jmm.0.47073-0.
7
Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses.皮肤α-人乳头瘤病毒样颗粒上B细胞表位的鉴定
J Virol. 2009 Dec;83(24):12692-701. doi: 10.1128/JVI.01582-09. Epub 2009 Sep 30.
8
Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.呈现人乳头瘤病毒6型（HPV-6）和人乳头瘤病毒16型（HPV-16）次要衣壳蛋白L2共同中和表位的嵌合人乳头瘤病毒16型（HPV-16）L1颗粒。
J Virol. 2003 Aug;77(15):8386-93. doi: 10.1128/jvi.77.15.8386-8393.2003.
9
Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.人乳头瘤病毒样颗粒的拆卸和组装产生更多类似病毒的抗体反应性。
Virol J. 2012 Feb 22;9:52. doi: 10.1186/1743-422X-9-52.
10
Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.人乳头瘤病毒33型主要衣壳蛋白中中和表位的特性分析
Virol J. 2006 Oct 2;3:83. doi: 10.1186/1743-422X-3-83.
引用本文的文献
1
Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.基于下一代 L2 的 HPV 疫苗可交叉保护免受皮肤乳头瘤病毒感染和肿瘤发展。
Front Immunol. 2022 Oct 3;13:1010790. doi: 10.3389/fimmu.2022.1010790. eCollection 2022.
2
Structural basis for the shared neutralization mechanism of three classes of human papillomavirus type 58 antibodies with disparate modes of binding.三类结合模式不同的人乳头瘤病毒58型抗体共享中和机制的结构基础
J Virol. 2021 Mar 10;95(7). doi: 10.1128/JVI.01587-20. Epub 2021 Jan 20.
3
Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.全面评估人乳头瘤病毒谱系变异对基于疫苗相关基因型主要衣壳蛋白的中和单克隆抗体识别的抗原性影响
J Virol. 2020 Nov 23;94(24). doi: 10.1128/JVI.01236-20.
4
Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.二价人乳头瘤病毒（HPV）疫苗对基因相关高危HPV感染变异株的交叉保护作用
J Infect Dis. 2016 Mar 15;213(6):939-47. doi: 10.1093/infdis/jiv519. Epub 2015 Oct 30.
5
Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.人乳头瘤病毒31型的天然衣壳蛋白变体代表单一L1血清型。
J Virol. 2015 Aug;89(15):7748-57. doi: 10.1128/JVI.00842-15. Epub 2015 May 20.
6
Identification of the neutralizing epitopes of Merkel cell polyomavirus major capsid protein within the BC and EF surface loops.在BC和EF表面环内鉴定默克尔细胞多瘤病毒主要衣壳蛋白的中和表位。
PLoS One. 2015 Mar 26;10(3):e0121751. doi: 10.1371/journal.pone.0121751. eCollection 2015.
7
Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.从成功的人类疫苗中汲取的经验教训：通过剖析衣壳蛋白来确定关键表位。
Hum Vaccin Immunother. 2015;11(5):1277-92. doi: 10.1080/21645515.2015.1016675.
8
Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy.HPV16 型假病毒，L1 主要衣壳蛋白 FG 环中存在少数点突变，可能逃避实际或未来的疫苗接种，用于基因治疗。
Mol Biotechnol. 2014 May;56(5):479-86. doi: 10.1007/s12033-014-9745-1.
9
Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.三种主要 HIV 疫苗诱导的人血清抗体反应特征，重点关注 Env 特异性抗体的诱导。
PLoS One. 2010 Nov 9;5(11):e13916. doi: 10.1371/journal.pone.0013916.
10
Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.包装有 L2 基因的乳头瘤病毒假病毒可诱导交叉中和抗体。
J Transl Med. 2010 Mar 24;8:28. doi: 10.1186/1479-5876-8-28.
本文引用的文献
1
Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women.人类乳头瘤病毒衣壳抗体对自然感染的反应以及HIV阳性和HIV阴性女性后续感染HPV的风险。
Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):283-8.
2
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.二价L1病毒样颗粒疫苗预防年轻女性感染人乳头瘤病毒16型和18型的疗效：一项随机对照试验
Lancet. 2004;364(9447):1757-65. doi: 10.1016/S0140-6736(04)17398-4.
3
Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.人乳头瘤病毒16型L1病毒样颗粒疫苗疗效的早期评估
Vaccine. 2004 Jul 29;22(21-22):2936-42. doi: 10.1016/j.vaccine.2003.11.059.
4
Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1.在主要衣壳蛋白L1的C末端臂上鉴定人乳头瘤病毒16型特异性表位。
J Virol. 2003 Nov;77(21):11625-32. doi: 10.1128/jvi.77.21.11625-11632.2003.
5
Human papillomavirus type 6 virus-like particles present overlapping yet distinct conformational epitopes.人乳头瘤病毒6型病毒样颗粒呈现出重叠但又不同的构象表位。
J Gen Virol. 2003 Jun;84(Pt 6):1493-1497. doi: 10.1099/vir.0.18872-0.
6
Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope.在人乳头瘤病毒16型病毒样颗粒的衣壳表面环上插入外源序列会降低其诱导中和抗体的能力，并界定出一个构象性中和表位。
Virology. 2003 Apr 25;309(1):32-40. doi: 10.1016/s0042-6822(02)00134-4.
7
Epidemiologic classification of human papillomavirus types associated with cervical cancer.与宫颈癌相关的人乳头瘤病毒类型的流行病学分类
N Engl J Med. 2003 Feb 6;348(6):518-27. doi: 10.1056/NEJMoa021641.
8
A controlled trial of a human papillomavirus type 16 vaccine.一项16型人乳头瘤病毒疫苗的对照试验。
N Engl J Med. 2002 Nov 21;347(21):1645-51. doi: 10.1056/NEJMoa020586.
9
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.人乳头瘤病毒L1主要衣壳蛋白内两个交叉中和线性表位的鉴定
J Virol. 2002 Jul;76(13):6480-6. doi: 10.1128/jvi.76.13.6480-6486.2002.
10
Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions.通过抑制人乳头瘤病毒（HPV）假病毒介导的基因转移来检测抗人乳头瘤病毒（HPV）的中和抗体。
J Clin Microbiol. 2002 Mar;40(3):926-32. doi: 10.1128/JCM.40.3.926-932.2002.
Zotero 插件